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Background: Fenofibric acid + statin combination therapy over 12 weeks results in more comprehensive improvement in mixed dyslipidemia than 
the individual monotherapies. This 2-year analysis evaluated the long-term efficacy and safety of fenofibric acid + rosuvastatin in patients with mixed 
dyslipidemia.
Methods: Patients were initially randomized to fenofibric acid, rosuvastatin, or fenofibric acid + rosuvastatin treatment for 12 weeks, which was 
followed by open-label treatment with fenofibric acid 135 mg + rosuvastatin 20 mg in 2 subsequent year-long extension studies (year 1 and 2). Only 
patients treated in the year 2 study were analyzed. Mean levels of efficacy and safety laboratory values at pretreatment baseline (week 0), week 64, 
and week 116, and mean percent changes from baseline to week 116 were evaluated. Data are summarized as observed.
Results: Baseline lipid levels (N=174) are consistent with mixed dyslipidemia (Table). Compared with baseline, all mean lipid levels were 
considerably improved at week 64 and week 116. Minor mean changes from week 0 to 116 were observed in the safety laboratory values. Adverse 
events tended to occur early in the treatment course and no new or unexpected muscle, hepatic, or renal safety signals occurred. 
Fenofibric acid 135mg + rosuvastatin 20mg effects on mean levels of variables, in year 2 population.
Baseline (Week 0)
N=174
Week 64
N=174
Week 116
N=161
Mean changea from baseline to week 116 ± SD
Efficacy
TG 289.2 128.6 137.5 −48.2 ± 22.61
HDL-C 38.4 48.1 45.0 19.2 ± 25.23
LDL-C 151.8 86.6
N=159
87.0
−40.9 ± 20.66
Non-HDL-C 221.2 110.5 113.2 −48.6 ± 13.58
Total-C 259.6 158.5 158.1 −38.7 ± 12.16
VLDL-C
N=167
70.3
N=167
24.0
N=152
26.6
−56.8 ± 25.17
Safety
ALT (U/L) 25.0
N=173
26.5
25.9 1.1 ± 12.70
CK (U/L) 134.8
N=173
184.8
144.7 10.2 ± 85.36
Creatinine 0.90 1.06 1.01 0.11 ± 0.147
Abbreviation: ALT, alanine aminotransferase; CK, creatine phosphokinase; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; SD, standard deviation; Non-HDL-C, non-high-density 
lipoprotein cholesterol; TG, triglycerides; Total-C, total cholesterol; VLDL-C, very low-density lipoprotein cholesterol
All values are means in mg/dL units, unless otherwise specified.
aMean percent changes are presented for the efficacy variables and mean changes are presented for the safety variables. The number of patients (N) for each variable is the same as the N for the week 116 mean.
Conclusion: This 2-year analysis demonstrates that the lipid efficacy of fenofibric acid 135 mg + rosuvastatin 20 mg is clinically favorable and 
sustained over time, without evidence of new or cumulative adverse events.
